Reality Check on Human Growth Hormones
Market access for human growth hormones reveals differences in payer coverage across each major channel, as well as specific trends in the drug landscape.
To help make sense of this new research, MMIT's team of experts has analyzed the data for you and summarized the key findings:
- Payer Insights: Increasing restrictions in the health exchange and medicare part d channels
- Class Trends: How biobetters on the horizon could shift prescribing habits
- Key Findings: How prior authorization and general restrictions dominate the HGH landscape
What can pharma do to curb this trend and overcome these challenges?
Get the data behind this change and how it could impact your market access plans from MMIT's team. Their clinical and policy backgrounds provide a unique and expert perspective to help expand your knowledge in the class and guide your decision-making process.
Download the full Reality Check now.